Clinical trial
Rilonacept to Improve Artery Function in Patients With Atherosclerosis
NCT00417417 · National Heart, Lung, and Blood Institute (NHLBI), NIH · Completed
Key facts
| NCT number | NCT00417417 |
|---|---|
| Title | Rilonacept to Improve Artery Function in Patients With Atherosclerosis |
| Official title | Effects of Interleukin-1 Inhibition on C-Reactive Protein Levels, Endothelial Progenitor Cell Mobilization and Endothelial Function in Patients With Coronary Artery Disease |
| Lead sponsor | National Heart, Lung, and Blood Institute (NHLBI), NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Coronary Artery Disease, Atherosclerosis, Inflammation, Endothelial Dysfunction |
| Intervention type | Drug |
| Interventions | Rilonacept, Placebo |
| Enrollment | 10 |
| Start date | Dec 1, 2006 |
| Primary completion | Apr 1, 2008 |
| Completion | Apr 1, 2008 |
| First posted | Jan 1, 2007 |
| Last update posted | Apr 30, 2012 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: